Abstract
Regulation of the manufacture of medicinal products in the UK was formalised by the Therapeutic Substances Act of 1925 which applied to sera and vaccines and other specified, usually biological, products. After the thalidomide tragedy a voluntary system of regulating the introduction of new drugs was introduced in 1963, under the aegis of the Committee on Safety of Drugs, often referred to as the Dunlop Committee (Cahal, 1968). This committee worked well, and provided a basis for the more elaborate legal control introduced by the Medicines Act of 1968. The working and consequences of this more elaborate process have recently been reviewed by Griffin and Diggle (1981) and Binns (1981). In other European countries the methods of regulation differ. In all countries the practical consequence has always been a growth, sometimes a rank growth, of detailed regulations about the assessment of the safety of potential new drugs. The UK has differed from most other countries in requiring extensive pharmacological and toxicological data before clinical trials are permitted, and a particularly lengthy procedure for approving applications. The position has been modified recently because the authority has conceded to pharmaceutical firms the facility, already open to doctors and dentists, to conduct studies on their own responsibility without undue bureaucratic interference (Griffin and Diggle, 1981). This concession appears to allow substantial administrative savings, although it is too early to know how it will work in practice.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Beeson, P. (1980). Medicine, Baltimore, 59, 79
Binns, T. B. (1981). Br. J. clin. Pharmac., 12, 449
Cahal, D. A. (1968). Can. med. Ass. J., 98, 271
Cavalla, J. F. (1978). Br. med. J., i, 1486
Gilette, R. J. (1976). In Drug Metabolism (ed. D. V. Parke and R. L. Smith), Taylor and Francis, London
Griffin, J. P., and Diggle, S. E. (1981). Br. J. clin. Pharmac., 12, 453
Gross, F. (1973). Acta pharm. Suecica, 10, 401
Hamre, D. M., Rake, G., McKee, C. M., and MacPhillamy, H. B. (1943). Am. J. med. Sci., 203, 642
Koppanyi, T., and Avery, M. A. (1965). Clin. Pharmac. Ther., 6, 250
Lunde, I., and Dukes, M. N. G. (1981). Eur. J. clin. Pharmac., 19, 1
Mitchell, J. R., Nelson, W. L., Potter, W. Z., Sasame, H. A., and Jollow, D. J. (1974). Nature, Lond., 251, 508
Newbould, B. B. (1981). In Risk-Benefit Analysis in Drug Research (ed. J. P. Cavalla), MTP Press, Lancaster
Richmond, H. G. (1959). Br. med. J., i, 947
Study Group of the Royal Society (1978).
Weatherall, M. (1981). Nature, Lond., in press
Weinbren, K. (1978). Br. med. J., i, 683
Wright, P. (1975). Br. med. J., i, 595
Editor information
Copyright information
© 1983 The Royal Society of Medicine
About this chapter
Cite this chapter
Weatherall, M. (1983). The Effects of Regulation on the Discovery, Supply and Cost of New Drugs. In: L’etang, H. (eds) Regulation and Restraint in Contemporary Medicine in the UK and USA. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-06501-1_5
Download citation
DOI: https://doi.org/10.1007/978-1-349-06501-1_5
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-06503-5
Online ISBN: 978-1-349-06501-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)